Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
A single glioblastoma patient's response to neoadjuvant checkpoint immunotherapy has prompted a formal randomized Phase II trial (GIANT, at Duke University, testing nivolumab with or without relatlimab).
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled INDIGO trial, vorasidenib significantly delayed disease progression (by blinded independent review) and delayed the time to the next anticancer intervention, compared with placebo, in a…
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled INDIGO trial, vorasidenib significantly delayed disease progression (by blinded independent review) and delayed the time to the next anticancer intervention, compared with placebo, in a…
Primary source cited
Last reviewed
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Case report, neoadjuvant checkpoint immunotherapy in glioblastoma (Nature Medicine) — reports ONE patient. DOI 10.1038/s41591-025-03512-1, PMID 40016450.
Eligibility varies — review trial criteria.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.